Friday, September 6, 2019 Daily Archives

MilliporeSigma buys data platform to bolster its Biopharma 4.0 offering

by

MilliporeSigma has bought the rights to the ProcessPad platform from Simplyfeye Softwares, adding the latest “building block” to its BioContinuum Platform. The ProcessPad platform from Simplyfeye Softwares Private Limited brings MilliporeSigma a data management and analytics solution capable of capturing development, scale-up, commercial and process data on a single platform as well as analyzing quantitative and qualitative batch manufacturing data. Financial details around the acquisition were not disclosed, but Michael Felo, director of Integrated Solutions Marketing, BioContinuum Platform, at MilliporeSigma,…

September 6, 2019

Avid contemplates pulling the trigger on capacity expansion

by

With new customers on board and a significant backlog, Avid Bioservices says it is making incremental expansions in its network ahead of a major investment. Contract development and manufacturing organization (CDMO) Avid Bioservices presented its Q1 FY2020 financials this week. Revenues stood at $15.3 million (€13.9 million) for the quarter, up 21% year-on-year, while revenue backlog increased 34% to $61 million. “The highlights for the first quarter of 2020 were new customer contracts, significant backlog growth and another successful process…

September 6, 2019

Introducing Cytiva: GE plans name change ahead of $21bn Danaher buy

by

GE Healthcare’s Biopharma business has announced plans to change its name and logo in anticipation of its acquisition by Danaher Corporation later this year. “On February 25 our lives changed,†Dodi Axelson, head of Communications, Life Sciences at GE Healthcare told Bioprocess Insider. She spoke, of course, about the agreement by Danaher Corporation to acquire the BioPharma portion of GE Healthcare’s Life Sciences business for a cash price of $21.4 billion (€19.4 billion). The deal is still under regulatory review…

September 6, 2019

FDA warns another unapproved cell therapy firm

by

The US FDA has slammed a self-described regenerative cellular therapy manufacturer for selling unapproved umbilical cord blood and umbilical cord products. California-based Stemell describes itself as an “organization dedicated to leadership, education, service, research and manufacturing of regenerative cellular and cell-free products,†making products StemL UCB-Plus and StemL UCT-Plus, derived from human umbilical cord blood and umbilical cord, for allogeneic use. However, in the latest example of a crackdown on unapproved stem cell therapies the firm has been at the…

September 6, 2019